on-interventional study to analyse the efectiveness and tolerance of chemotherapy with Docetaxel NC(R) or Doce NC (R) during the treatment of breast cancer and prostate cancer as an application for the daily routine

• Conditions: C50; C61; Malignant neoplasm of breast; Malignant neoplasm of prostate

• Registration Number: DRKS00004502
• Lead Sponsor: eocorp GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-12-14
• Study Completion: 2014-11-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

Histological backed prostate carcinoma or breast cancer, Age over 18 Years, signed patient informed consent, therapy in a practice, which belongs to BNGO or IQUO.

Exclusion Criteria

Pregnancy, other malignant diseases in the last 5 years, malignant compliance

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
tolerance evaluated by the NCI CTCAE Criteria

Secondary Outcome Measures

Name	Time	Method
efficacy evaluated by the objective response